In the past few years pharmaceutical companies have developed a string of new Alzheimer’s drugs called anti-amyloids, which target amyloid plaques in patients’ brains. These plaques are one of the key biomarkers of the disease.
The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.
In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.
Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.
From the outside looking in, these Alzheimer’s drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?
To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine, and co-director of the Penn Memory Center.
Transcripts for each segment will be available after the show airs on sciencefriday.com.
Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
748: Investigating Animal Deaths At The National Zoo
745: Eating More Oysters Helps Us—And The Chesapeake Bay
747: How Trees Keep D.C. And Baltimore Cool
744: Predicting Heart Disease From Chest X-Rays With AI | Storing New Memories During Sleep
746: Recipient Of Pig Kidney Transplant Recovering | Answering Your Questions About April 8 Eclipse
743: Our Inevitable Cosmic Apocalypse
742: The Complicated Truths About Offshore Wind And Right Whales
740: ‘3 Body Problem’ And The Laws Of Physics | In Defense Of ‘Out Of Place’ Plants
739: Baltimore Bridge Collapse | Mapping How Viruses Jump Between Species
738: The Legacy Of Primatologist Frans de Waal
737: The ‘Asteroid Hunter’ Leading The OSIRIS-REx Mission
736: Swimming Sea Lions Teach Engineers About Fluid Dynamics
735: Botanical Rescue Centers Take In Illegally Trafficked Plants
734: 2023 Was Hottest Year On Record | The NASA Satellite Studying Plankton
731: A Strange-Looking Fish, Frozen In Time
732: What We Know After 4 Years Of COVID-19
733: Science Unlocks The Power Of Flavor In ‘Flavorama’
729: Abortion-Restrictive States Leave Ob-Gyns With Tough Choices
730: Nasal Rising Safely | How Your Brain Constructs Your Mental Health
Create your
podcast in
minutes
It is Free
The Modern West
Just Dumb Enough Podcast
Voices of Misery Podcast
House of Whimsical Terror
Stuff You Should Know
Timcast IRL